Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Reply to letter to the editor.

de Jong HJI, Tremlett H, Zhu F, Ascherio A, Munger KL.

Mult Scler Relat Disord. 2019 Sep;34:165. doi: 10.1016/j.msard.2019.06.025. Epub 2019 Jun 20. No abstract available.

PMID:
31543260
2.

Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.

Marrie RA, Tremlett H, Kingwell E, Schaffer SA, Yogendran M, Zhu F, Fransoo R, Garland A.

Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038. [Epub ahead of print]

PMID:
31517571
3.

Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.

Schwehr NA, Kuntz KM, Butler M, Enns EA, Shippee ND, Kingwell E, Tremlett H, Carpenter AF; BeAMS Study Group.

Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613. [Epub ahead of print]

PMID:
31354041
4.

Higher health care use before a clinically isolated syndrome with or without subsequent MS.

Marrie RA, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Tremlett H.

Mult Scler Relat Disord. 2019 Jul 2;35:42-49. doi: 10.1016/j.msard.2019.07.002. [Epub ahead of print]

PMID:
31319354
5.

Adjusting for differential misclassification in matched case-control studies utilizing health administrative data.

Högg T, Zhao Y, Gustafson P, Petkau J, Fisk J, Marrie RA, Tremlett H.

Stat Med. 2019 Aug 30;38(19):3669-3681. doi: 10.1002/sim.8203. Epub 2019 May 21.

PMID:
31115088
6.

Multiple sclerosis: effect of beta interferon treatment on survival.

Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, Tremlett H.

Brain. 2019 May 1;142(5):1324-1333. doi: 10.1093/brain/awz055.

7.

Traditional risk factors may not explain increased incidence of myocardial infarction in MS.

Marrie RA, Garland A, Schaffer SA, Fransoo R, Leung S, Yogendran M, Kingwell E, Tremlett H.

Neurology. 2019 Apr 2;92(14):e1624-e1633. doi: 10.1212/WNL.0000000000007251. Epub 2019 Mar 6. Erratum in: Neurology. 2019 Sep 10;93(11):518.

PMID:
30842298
8.

Socioeconomic status and disability progression in multiple sclerosis: A multinational study.

Harding KE, Wardle M, Carruthers R, Robertson N, Zhu F, Kingwell E, Tremlett H.

Neurology. 2019 Mar 26;92(13):e1497-e1506. doi: 10.1212/WNL.0000000000007190. Epub 2019 Feb 22.

PMID:
30796140
9.

Validation of an algorithm for identifying MS cases in administrative health claims datasets.

Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG; United States Multiple Sclerosis Prevalence Workgroup (MSPWG).

Neurology. 2019 Mar 5;92(10):e1016-e1028. doi: 10.1212/WNL.0000000000007043. Epub 2019 Feb 15.

10.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15. Erratum in: Neurology. 2019 Oct 8;93(15):688.

11.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):469-480. doi: 10.1212/WNL.0000000000007044. Epub 2019 Feb 15. Review.

12.

Prodrome in relapsing-remitting and primary progressive multiple sclerosis.

Wijnands JMA, Zhu F, Kingwell E, Zhao Y, Evans C, Fisk JD, Marrie RA, Tremlett H.

Eur J Neurol. 2019 Jul;26(7):1032-1036. doi: 10.1111/ene.13925. Epub 2019 Mar 1.

PMID:
30714270
13.

A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?

Forbes JD, Bernstein CN, Tremlett H, Van Domselaar G, Knox NC.

Front Microbiol. 2019 Jan 9;9:3249. doi: 10.3389/fmicb.2018.03249. eCollection 2018. Review.

14.

MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis.

Wijnands JMA, Ekuma O, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H, Marrie RA.

Mult Scler Relat Disord. 2019 Feb;28:138-144. doi: 10.1016/j.msard.2018.12.030. Epub 2018 Dec 23.

PMID:
30594814
15.

Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.

Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, Evans C, Tremlett H.

Mult Scler Relat Disord. 2019 Jan;27:364-369. doi: 10.1016/j.msard.2018.11.004. Epub 2018 Nov 9.

PMID:
30476872
16.

Animal exposure over the life-course and risk of multiple sclerosis: A case-control study within two cohorts of US women.

de Jong HJI, Tremlett H, Zhu F, Ascherio A, Munger KL.

Mult Scler Relat Disord. 2019 Jan;27:327-332. doi: 10.1016/j.msard.2018.11.015. Epub 2018 Nov 15.

PMID:
30471586
17.

Coexistence of Multiple Sclerosis and Alzheimer's disease: A review.

Luczynski P, Laule C, Hsiung GR, Moore GRW, Tremlett H.

Mult Scler Relat Disord. 2019 Jan;27:232-238. doi: 10.1016/j.msard.2018.10.109. Epub 2018 Oct 27. Review.

PMID:
30415025
18.

Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course.

Nourbakhsh B, Bhargava P, Tremlett H, Hart J, Graves J, Waubant E.

Ann Clin Transl Neurol. 2018 Sep 27;5(10):1211-1221. doi: 10.1002/acn3.637. eCollection 2018 Oct.

19.

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.

Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Lilford R, Dobson C.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260. doi: 10.1136/jnnp-2018-318360. Epub 2018 Sep 21.

20.

Identifying optic neuritis and transverse myelitis using administrative data.

Marrie RA, Ekuma O, Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:258-264. doi: 10.1016/j.msard.2018.08.013. Epub 2018 Aug 13.

PMID:
30144696
21.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:232-240. doi: 10.1016/j.msard.2018.08.007. Epub 2018 Aug 8.

PMID:
30121490
22.

Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.

Setayeshgar S, Kingwell E, Zhu F, Zhang X, Zhang T, Marrie RA, Carruthers R, Tremlett H.

Mult Scler Relat Disord. 2018 Oct;25:57-60. doi: 10.1016/j.msard.2018.07.012. Epub 2018 Jul 9.

PMID:
30036855
23.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

24.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2019 Jul;25(8):1092-1101. doi: 10.1177/1352458518783662. Epub 2018 Jul 6.

PMID:
29979093
25.

Predicting risk of secondary progression in multiple sclerosis: A nomogram.

Manouchehrinia A, Zhu F, Piani-Meier D, Lange M, Silva DG, Carruthers R, Glaser A, Kingwell E, Tremlett H, Hillert J.

Mult Scler. 2019 Jul;25(8):1102-1112. doi: 10.1177/1352458518783667. Epub 2018 Jun 18.

PMID:
29911467
26.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018;51(1-2):1-10. doi: 10.1159/000488799. Epub 2018 May 15.

PMID:
29763935
27.

Can falling infection rates in one country explain rising incidence of autoimmune and allergic diseases in other countries? Caution when (over) interpreting ecological data from disparate areas.

Tremlett H, Rodney R, Lucas R.

Mult Scler Relat Disord. 2018 Apr;21:A3-A5. doi: 10.1016/j.msard.2017.11.001. Epub 2017 Nov 3. No abstract available.

PMID:
29724378
28.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

29.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056. doi: 10.1136/jnnp-2017-317493. Epub 2018 Mar 30.

PMID:
29602795
30.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

31.

Sun exposure over the life course and associations with multiple sclerosis.

Tremlett H, Zhu F, Ascherio A, Munger KL.

Neurology. 2018 Apr 3;90(14):e1191-e1199. doi: 10.1212/WNL.0000000000005257. Epub 2018 Mar 7.

32.

The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset.

Amram O, Schuurman N, Randall E, Zhu F, Saeedi J, Rieckmann P, Yee I, Tremlett H.

Mult Scler Relat Disord. 2018 Apr;21:30-34. doi: 10.1016/j.msard.2018.02.005. Epub 2018 Feb 6.

PMID:
29455071
33.

Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011-2016).

Charron S, McKay KA, Tremlett H.

Mult Scler Relat Disord. 2018 Feb;20:169-177. doi: 10.1016/j.msard.2018.01.021. Epub 2018 Feb 2. Review.

PMID:
29414293
34.

Gut microbiome and pediatric multiple sclerosis.

Tremlett H, Waubant E.

Mult Scler. 2018 Jan;24(1):64-68. doi: 10.1177/1352458517737369. Review.

PMID:
29307301
35.

Effects of physical comorbidities on disability progression in multiple sclerosis.

Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Carruthers R, Wolfson C, Warren S, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

36.

Drug exposure and the risk of multiple sclerosis: A systematic review.

Yong HY, McKay KA, Daley CGJ, Tremlett H.

Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):133-139. doi: 10.1002/pds.4357. Epub 2017 Dec 6.

PMID:
29210147
37.

Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2017 Dec 12;89(24):2455-2461. doi: 10.1212/WNL.0000000000004716. Epub 2017 Nov 8.

38.

Author response: Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

Tremlett H.

Neurology. 2017 Nov 7;89(19):2022-2023. doi: 10.1212/WNL.0000000000004621. No abstract available.

PMID:
29109136
40.

Concussion may not cause multiple sclerosis.

Wijnands JMA, Tremlett H.

Ann Neurol. 2017 Oct;82(4):651-652. doi: 10.1002/ana.25061. Epub 2017 Oct 14. No abstract available.

PMID:
28976601
41.

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study.

Zhang T, Kingwell E, Zhu F, Petkau J, Kastrukoff LF, Marrie RA, Tremlett H, Evans C.

BMJ Open. 2017 Sep 29;7(9):e018612. doi: 10.1136/bmjopen-2017-018612.

42.

The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings.

Tremlett H, Waubant E.

Neurotherapeutics. 2018 Jan;15(1):102-108. doi: 10.1007/s13311-017-0574-3. Review.

43.

Bayesian analysis of pair-matched case-control studies subject to outcome misclassification.

Högg T, Petkau J, Zhao Y, Gustafson P, Wijnands JM, Tremlett H.

Stat Med. 2017 Nov 20;36(26):4196-4213. doi: 10.1002/sim.7427. Epub 2017 Aug 7.

PMID:
28783882
44.

Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.

McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H.

Neuroepidemiology. 2017;48(3-4):124-130. doi: 10.1159/000477771. Epub 2017 Jul 7.

PMID:
28683461
45.

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.

Kowalec K, Kingwell E, Carruthers R, Marrie RA, Bernatsky S, Traboulsee A, Ross CJD, Carleton B, Tremlett H.

BMJ Open. 2017 Jun 2;7(5):e016276. doi: 10.1136/bmjopen-2017-016276.

46.

Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H; British Columbia Multiple Sclerosis Clinic Neurologists.

Neurology. 2017 Jun 13;88(24):2310-2320. doi: 10.1212/WNL.0000000000004037. Epub 2017 May 12.

47.

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Högg T, Stadnyk K, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Lancet Neurol. 2017 Jun;16(6):445-451. doi: 10.1016/S1474-4422(17)30076-5. Epub 2017 Apr 20.

PMID:
28434855
48.

Increased incidence and prevalence of psoriasis in multiple sclerosis.

Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD.

Mult Scler Relat Disord. 2017 Apr;13:81-86. doi: 10.1016/j.msard.2017.02.012. Epub 2017 Feb 20.

49.

Determinants of neurological disease: Synthesis of systematic reviews.

Krewski D, Barakat-Haddad C, Donnan J, Martino R, Pringsheim T, Tremlett H, van Lieshout P, Walsh SJ, Birkett NJ, Gomes J, Little J, Bowen S, Candundo H, Chao TK, Collins K, Crispo JAG, Duggan T, El Sherif R, Farhat N, Fortin Y, Gaskin J, Gupta P, Hersi M, Hu J, Irvine B, Jahanfar S, MacDonald D, McKay K, Morrissey A, Quach P, Rashid R, Shin S, Sikora L, Tkachuk S, Taher MK, Wang MD, Darshan S, Cashman NR.

Neurotoxicology. 2017 Jul;61:266-289. doi: 10.1016/j.neuro.2017.04.002. Epub 2017 Apr 12. Review.

PMID:
28410962
50.

Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.

Evans C, Marrie RA, Zhu F, Leung S, Lu X, Kingwell E, Zhao Y, Tremlett H.

Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):702-711. doi: 10.1002/pds.4207. Epub 2017 Apr 3.

PMID:
28370875

Supplemental Content

Loading ...
Support Center